Gavin Teo

Tech Investor in Private Markets

📍 Singapore, Singapore🔄 Updated September 2026💼 14 investments📅 9 years investing🗓 Last invested Oct 2025𝕏 @upgrade_to_unlock
VC🌍 SingaporeInvested this year
14
Total investments
1
Early stage
5
Mid stage
7
Late stage
9y
Years active

Portfolio

14 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Oct 2025
reach52 is a health impact innovator dedicated to redesigning healthcare to reach 52% of the world that cannot access essential healthcare products and services. The reach52 Group comprises three purpose-driven business units: reach52 Impact, reach52 Access and reach52 Insights, specialising in community health interventions, health worker training, manufacturing and distribution of essential public health commodities, and research, data and insights. Together, they join the dots of healthcare access, working towards reach52’s collective vision of enabling affordable healthcare for anyone on earth. https://impact.reach52.com/ reach52 Impact focuses on community health interventions and health worker training in emerging markets that help underserved residents access essential services. Our network of reach52 Health Educators use our offline-first app to collect data on local needs, run health education and screening events, and target the most at-risk residents in underserved communities through one-on-one engagements. https://access.reach52.com/ reach52 Access launches, distributes and promotes affordable high-quality essential medicines and health products across emerging markets; with integrated health worker training, education and screening interventions. reach52 Insights collects, integrates and analyses broad health data from emerging markets, allowing us and our partners to understand trends, opportunities and market insights.
Board Member
Dec 2023
Jaringan Klinik Digital #1 di Indonesia
Board Member
Oct 2022
KYAN Technologies, a pioneering leader in the field of precision medicine for oncology. Our company is dedicated to revolutionizing cancer care by leveraging cutting-edge technology and expertise. At KYAN, we have developed Optim.AI, a state-of-the-art Functional Precision Medicine test. This powerful tool empowers oncologists by providing them with critical insights to make informed clinical decisions for their patients. Our core mission is to bridge the existing gap in cancer care, and we achieve this through our unique specialization in integrating small data AI and biological experiments. Through our proprietary platform, we offer an efficient solution that transforms the identification of optimal outcomes from vast drug-dose combinations, revolutionizing the development and delivery of therapies to patients. In addition to our groundbreaking technology, KYAN is committed to conducting extensive research studies across various cancer indications, including Colorectal and Breast Cancer. These studies not only contribute to the advancement of biopharma services but also aid in the development of novel biopharmaceutical assets.
Board Member
May 2022
SATURDAYS is a lifestyle brand that offers a wide selection of designer quality yet affordable eyewear, which is designed in-house to fit and look great. We provide convenient, omnichannel experiences through our app, home try-on service and lifestyle stores, where customers can also enjoy specialty coffee and fresh baked cookies. Shop when you want, how you want.
late stageRetail
Board Member
Mar 2022
Med247 is a hybrid Offline-to-Online (O2O) healthcare startup, which runs its own chain of convenient family doctor clinics in Vietnam. Med247 offers a holistic healthcare experience with our App Med247, which enables patients to book for no-wait appointment with their favorite doctor at the chain clinics, 24/7 telemedicine (incl. doctor consultation via chat or video call), online prescription delivered right to your doorstep, electronic health record (EHRs), online payment, medication reminder, practical healthcare tips and more. Clinic in-person visits and online activities are synchronised with automation allowing pushed personalised health-check warning and doctor's recommendations. Our clinic management system (CMS) and Doctors/Patients App are specifically developed in-house to ensure optimal security and personal data protection. Med247's vision is to leverage technological advantages to develop an ecosystem of product and services that transcends urgent care into primary care and well-being, building a healthier Vietnam.
Board Member
Sep 2021
Clevai is a leading online K-12 Math tutoring provider in Vietnam. It became a Top-3 online math provider only 2 years after founding, by combining celebrity Dual-Teacher livestreaming, small-group Adaptive Tutoring, and vibrant gamification to deliver 4.8-rated courses. Clevai is a pioneer in applying technology in education and the organizer of the TechForStudy seminar series with over 20 speakers: tech leaders from VinAI, Earable, Ohmnibot, etc., and scholars from Harvard, Oxford, etc., several of whom are serving as the company’s advisors. Clevai received investment from Altara Ventures, FEBE Ventures, and FJ Labs and was listed as one of the "Emerging Giants in Asia-Pacific 2022" by HSBC and KPMG. It plans to expand into South East Asia and secure a place among the Top 5 online education ecosystems in the region within 5 years.
Board Member
Jan 2021
Staffinc is Indonesia’s leading digital staffing platform, covering the end to end workforce needs for established businesses and aspiring enterprises alike. Our services include: - Staffing: providing you skilled and curated workers from various industries, managing their recruitments to payrolls. - HR system: a software suite designed to provide maximum ease and visibility in recruiting, managing, payrolling, and providing benefits for your workers. - Procurement and rental: Equipping your workers with all the right tools for the job from laptops to vehicles. Established in 2018, Staffinc employs more than 1.500.000+ workers across 350+ cities in Indonesia, empowering businesses and workers alike to achieve their goals and create meaningful impact. At Staffinc, we pride ourselves in being powered by people, scaled through technology.
Board Member
Aug 2019
CXA Group is Asia’s one-stop, predictive and data intelligence platform for better health, wealth and wellness choices. Through the CXA platform, employers can empower employees with access to personalised health and lifestyle offerings, with clear and quantifiable ROI for the business. We enable employers to leverage their existing healthcare and insurance spend to pay for flexible benefits, corporate wellness and disease management initiatives in order to improve health, combat chronic disease and reduce costs while allowing for employee personalization via an e-wallet and AI. Headquartered in Singapore, CXA achieved revenue growth of 65 percent in 2018 and is expected to double that in 2019. It announced a funding round in March 2019 of USD 25 million. This follows US$33 million in total funding from Series A and B in 2015 and 2017 respectively. CXA’s investors include HSBC, Singtel Innov8, Telkom Indonesia MDI Ventures, Sumitomo Corporation Equity Asia, Muang Thai Fuchsia Ventures, Humanica and Heritas Venture Fund B Capital Group, Openspace Ventures, Government-linked strategic investor EDBI, BioVeda Capital, FengHe Asia, Philips and RGAx. Driven by a team of industry veterans with extensive leadership experience across Asia’s human resource, insurance, finance, healthcare and technology industries, CXA serves more than 600 enterprises, including Fortune 500 companies, and more than 400,000 employees in 20 countries. CXA has received recognition as InsurTech of the Year from the Asia Insurance Industry Awards and was among the top three most impactful innovations at the Singapore Digital Techblazer Awards. We were also voted Best Corporate Wellness Consultant and Best Compensation & Benefits Consultant, Best Corporate Employee Rewards and won the Asian Insurance Innovation Award. CXA was one of only 7 global health tech startups to be selected to join the Innovations in Healthcare network founded by Duke Health, McKinsey & Co., and the World Economic Forum
Board Member
May 2018
Galen Growth is your partner for Digital Health market intel: for comprehensive data, empirical research, and expert insights. We are here to help you reach the optimal solution for your business transformation, discover the latest trends in Digital Health, and strengthen your innovative capabilities. Our HealthTech Alpha platform transforms how leaders of corporations make decisions. Our offerings include: 1. DATA - Reshape your view on the Digital Health ecosystem in just a few clicks with HealthTech Alpha, our Digital Health private market database, and get an accurate picture of the market to drive your next Digital Health solution. 2. RESEARCH - Gain valuable insights on the latest in Digital Health by availing our empirical research reports, and leverage on our inspired thought-leadership content to learn more about the Digital Health landscape. 3. ADVISORY - Create your winning edge over your competitors by consulting our team of Digital Health experts to optimize your business strategy, conduct competitor benchmarking, and achieve your strategic goals through our Innovation Playbook. Over the last few years, Digital Health has been transforming how society interacts with healthcare. Galen Growth was created to empower the world’s leading companies to connect with the ever-evolving digital health ecosystem, so that you can deliver better data-driven outcomes for your business, customers, and society. Join us on this journey for a better future for Digital Health. To learn more about our company and services, visit our website at galengrowth.com and follow this page for regular updates. To get started with HealthTech Alpha, visit healthechalpha.com to access our data platform and kickstart your next Digital Health solution.
Board Member
Mar 2018
Fishbrain is a passionate and collaborative community with the tools you need to have the best possible fishing experience. With 200 million people sport fishing around the world, we’re connecting anglers to make fishing dreams come true, today and tomorrow. Here are some impressive stats: 15 million anglers use the platform, and have logged over 14 million catches. On any given day, Fishbrain lets you choose from over 1.7 million fishing locations worldwide. With all the new fishing information that keeps rolling in from our anglers, our engineers crunch the numbers to make the world’s best data-driven fishing recommendations. The Fishbrain experience happens in our mobile app, and we have some pretty cool features: - See where the big fish will be biting with our Fishing Forecast. - Share catches and moments with fellow anglers. - Explore catches and fishing spots on a local map. - Log your catches and track your personal angling progress. As a company, we value diversity. Some of us are anglers. Some of us are parents. All of us are human. We’re passionate about the outdoors and conservation. We have an open work culture. We have core values that we bring to life on a daily basis. Our Stockholm office is a cubicle-free, well-lit place, where teamwork is fluid and ongoing, and there’s always coffee brewing. Why dont you join us? See all open positions at http://fishbrain.com/jobs/ Download the app at www.fishbrain.com.
Board Member
Feb 2018
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers
Board Member
Jan 2018
We are one of the largest independent automated driving technology providers in the world. Our holistic approach to driving automation tackles three main industry challenges: software, development and validation tools, and processing hardware. Our team of over 230 works in offices in the USA, Japan, and Hungary to ensure our products are solving the real-world challenges of driving automation. We rely on our team’s expertise in artificial intelligence, sensor fusion, 3D graphics and real-world automated driving workloads, developed utilizing our global test fleet to provide robust solutions. As a result, our market-ready products can accelerate the safe and affordable deployment of ADAS and automated driving bringing these life-saving technologies to the public sooner.
mid stageAutomotive
Board Member
Jul 2017
Making Healthy Happen Faster. Bright.md is the leading virtual care solution trusted by health systems to automate clinical workflows and administrative tasks, improving patient and provider engagement and driving operational efficiency. With its pioneering technology, Bright.md improves how health systems deliver care, from patient acquisition through clinical interview and treatment, to reduce 90% of administrative workflows, lower patient wait-times to 6 minutes on average, and drive patient loyalty with industry-leading satisfaction ratings. Founded in 2014 and based in Portland, Oregon, Bright.md has been named a Gartner Cool Vendor in Healthcare, a Vendor to Watch by Chilmark Research, and is the preferred choice of AVIA’s Virtual Access cohort. Bright.md is backed by B Capital Group, Seven Peaks Ventures, Pritzker Group Venture Capital, Philips Health Technology Ventures, UnityPoint Health, and Concord Health Partners.
Board Member
Jan 2017
SilverCloud® by Amwell® (NYSE: AMWL) is a leading digital mental health platform, enabling providers, health plans and employers to deliver clinically validated digital health/therapeutic care that improves outcomes and increases access and scale while reducing costs. Developed in Ireland in 2012, the multi-award-winning digital mental health platform is a result of 20 years of clinical research with leading academic institutions. Today, SilverCloud® is being used by more than 500 organizations globally to meet their populations’ mental health needs. Global experts have clinically proven the platform through fully randomized control trials and anonymized, real-world data from over one million SilverCloud users. The platform is a leader in the industry with its effectiveness, engagement and range of clinical programs that encompasses the spectrum of mental health needs.
Experience · 24 entries
All (24)
Investments (14)
Founder (1)
Board (14)
2026
Co-Founder
2026
AIQ Worldwide provides small- and medium-sized enterprises (SMEs) the expertise and resources to unlock the power of artificial intelligence and cloud technologies to transform their business. We acquire SMEs led by ambitious teams ready to harness AI and cloud technologies to fuel long-term global growth. Our proprietary "Three-Dimensional Transformation (3DT)" methodology helps our SME leadership teams rapidly streamline operations, fuel product innovation, and accelerate go-to-market motions. And, because we are a permanent capital holding company, we can focus on helping our companies make the right long-term investment decisions, and we can reinvest earnings back into growing our companies and our people.
2025
Board Member
Oct 2025
reach52 is a health impact innovator dedicated to redesigning healthcare to reach 52% of the world that cannot access essential healthcare products and services. The reach52 Group comprises three purpose-driven business units: reach52 Impact, reach52 Access and reach52 Insights, specialising in community health interventions, health worker training, manufacturing and distribution of essential public health commodities, and research, data and insights. Together, they join the dots of healthcare access, working towards reach52’s collective vision of enabling affordable healthcare for anyone on earth. https://impact.reach52.com/ reach52 Impact focuses on community health interventions and health worker training in emerging markets that help underserved residents access essential services. Our network of reach52 Health Educators use our offline-first app to collect data on local needs, run health education and screening events, and target the most at-risk residents in underserved communities through one-on-one engagements. https://access.reach52.com/ reach52 Access launches, distributes and promotes affordable high-quality essential medicines and health products across emerging markets; with integrated health worker training, education and screening interventions. reach52 Insights collects, integrates and analyses broad health data from emerging markets, allowing us and our partners to understand trends, opportunities and market insights.
2023
Board Member
Dec 2023
Jaringan Klinik Digital #1 di Indonesia
2022
Board Member
Oct 2022
KYAN Technologies, a pioneering leader in the field of precision medicine for oncology. Our company is dedicated to revolutionizing cancer care by leveraging cutting-edge technology and expertise. At KYAN, we have developed Optim.AI, a state-of-the-art Functional Precision Medicine test. This powerful tool empowers oncologists by providing them with critical insights to make informed clinical decisions for their patients. Our core mission is to bridge the existing gap in cancer care, and we achieve this through our unique specialization in integrating small data AI and biological experiments. Through our proprietary platform, we offer an efficient solution that transforms the identification of optimal outcomes from vast drug-dose combinations, revolutionizing the development and delivery of therapies to patients. In addition to our groundbreaking technology, KYAN is committed to conducting extensive research studies across various cancer indications, including Colorectal and Breast Cancer. These studies not only contribute to the advancement of biopharma services but also aid in the development of novel biopharmaceutical assets.
Board Member
May 2022
SATURDAYS is a lifestyle brand that offers a wide selection of designer quality yet affordable eyewear, which is designed in-house to fit and look great. We provide convenient, omnichannel experiences through our app, home try-on service and lifestyle stores, where customers can also enjoy specialty coffee and fresh baked cookies. Shop when you want, how you want.
late stageRetail
Show all 24 entries ↓
Investment activity
2017–2025 · 14 investments
20172201842019120212202232023120251
Recent (last 2 years)Earlier